Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer

References

• Oostveen EA, Speckamp WN. Mitomycin analogs I. Indolequinones as (potential) bisalkylating agents. Tetrahedron. 1987;43:255–262.
   Web of Science ®Google Scholar
• Hendriks HR, Pizao PE, Berger DP, et al. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer. 1993;29A:897–906.
   PubMed Web of Science ®Google Scholar
• Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol. 2016;77:441–457.
   PubMed Web of Science ®Google Scholar
• Hunter FW, Wouters BG, Wilson WR. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer. 2016;114:1071–1077.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer. 1998;77:2112–2119.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Hendriks HR, Peters GJ, et al. EO9 (apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol. 2013;168:11–18.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Cheng L, Montironi R, Davidson DD, et al. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(Suppl 2):S70–95.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 2008;53:45–52.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–1029.
   PubMed Web of Science ®Google Scholar
• Abern MR, Owusu RA, Anderson MR, et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw. 2013;11:477–484.
   PubMed Web of Science ®Google Scholar
• Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64:421–430.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–90, quiz 435.
   PubMed Web of Science ®Google Scholar
• Jarow J, Maher VE, Tang S, et al. Development of systemic and topical drugs to treat non-muscle invasive bladder cancer. Bladder Cancer. 2015;1:133–136.
   PubMedGoogle Scholar
• Barocas DA, Globe DR, Colayco DC, et al. Surveillance and treatment of non-muscle-invasive bladder cancer in the USA. Adv Urol. 2012;2012:421709.
   PubMedGoogle Scholar
• Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology. 2000;55:161–168.
   PubMed Web of Science ®Google Scholar
• Panach-Navarrete J, Ferrandis-Cortes C, Sales-Maicas MA, et al. Mitomycin extravasation after postoperative instillation. Arch Esp Urol. 2015;68:633–636.
   PubMed Web of Science ®Google Scholar
• Lim D, Izawa JI, Middlebrook P, et al. Bladder perforation after immediate postoperative intravesical instillation of mitomycin C. Can Urol Assoc J. 2010;4:E1–3.
   PubMedGoogle Scholar
• De Jager R, Guinan P, Lamm D, et al. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials. Urology. 1991;38:507–513.
   PubMed Web of Science ®Google Scholar
• Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park). 1995;9:947-52, 55, discussion 55-65.
   PubMedGoogle Scholar
• Svatek RS, Hollenbeck BK, Holmang S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66:253–262.
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27:295–300.
   PubMed Web of Science ®Google Scholar
• Guancial EA, Roussel B, Bergsma DP, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015;10:939–949.
   PubMed Web of Science ®Google Scholar
• Soria F, Moschini M, Korn S, et al. How to optimally manage elderly bladder cancer patients? Transl Androl Urol. 2016;5:683–691.
   PubMed Web of Science ®Google Scholar
• EO9 to be licenced by Kyowa Hakko Kogyo. Ann Oncol. 1994;5:2.
   PubMedGoogle Scholar
• van der Schoot SC, Nuijen B, Flesch FM, et al. Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS Pharmscitech. 2007;8:E78–E87.
   PubMed Web of Science ®Google Scholar
• van der Schoot SC, Vainchtein LD, Beijnen JH, et al. Bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies. Int J Pharm. 2007;329:135–141.
   PubMed Web of Science ®Google Scholar
• Vainchtein LD, Rosing H, Mirejovsky D, et al. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. J Pharm Biomed Anal. 2007;43:285–292.
   PubMed Web of Science ®Google Scholar
• Comer E, Murphy WS. The bromoquinone annulation reaction: a formal total synthesis of EO9. Archive Org Chem. 2003;2003:286–296.
   Google Scholar
• Cotterill AS, Moody CJ, Roffey JRA. An improved synthesis of the indolequinone anticancer agent EO9. Tetrahedron. 1995;51:7223–7230.
   Web of Science ®Google Scholar
• Kinugawa M, Arai H, Nishikawa H, et al. Facile synthesis of the key intermediate of EO9 via the formation of the indole skeleton using the Nenitzescu reaction. J Chem Soc Perkin Trans. 1995;1:2677–2678.
   Google Scholar
• Kinugawa M, Masuda Y, Arai H, et al. Large scale synthesis of the high quality indoloquinone antitumor agent EO 9 via [Bis(trifluoroacetoxy)iodo]benzene oxidation of 4-aminoindole. Synthesis. 1996;1996:633–636.
   Google Scholar
• Kinugawa M, Rai H, Ogasa T, et al. Development of large-scale synthetic process for antitumor agent EO9. J Synth Org Chem Jpn. 1999;57:401–406.
   Web of Science ®Google Scholar
• Butler J, Spanswick VJ, Cummings J. The autoxidation of the reduced forms of EO9. Free Radic Res. 1996;25:141–148.
   PubMed Web of Science ®Google Scholar
• Bailey SM, Lewis AD, Patterson LH, et al. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol. 2001;62:461–468.
   PubMed Web of Science ®Google Scholar
• Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991;3:199–206.
   PubMed Web of Science ®Google Scholar
• Bailey SM, Wyatt MD, Friedlos F, et al. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br J Cancer. 1997;76:1596–1603.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Wolfs A, Groot SE, et al. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer. 1995;71:836–839.
   PubMed Web of Science ®Google Scholar
• Phillips RM. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. Biochem Pharmacol. 1996;52:1711–1718.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Ward TH. Influence of extracellular pH on the cytotoxicity and DNA damage of a series of indolequinone compounds. Anticancer Res. 2001;21:1795–1801.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons SA, Workman P, Grever M, et al. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996;88:259–269.
   PubMed Web of Science ®Google Scholar
• Plumb JA, Gerritsen M, Milroy R, et al. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 1994;29:295–299.
   PubMed Web of Science ®Google Scholar
• Robertson N, Haigh A, Adams GE, et al. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer. 1994;30A:1013–1019.
   PubMed Web of Science ®Google Scholar
• Smitskamp-Wilms E, Peters GJ, Pinedo HM, et al. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol. 1994;47:1325–1332.
   PubMed Web of Science ®Google Scholar
• Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer. 1994;56:134–139.
   PubMed Web of Science ®Google Scholar
• Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;75:69–75.
   PubMed Web of Science ®Google Scholar
• Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res. 1994;6:461–475.
   PubMed Web of Science ®Google Scholar
• Collard J, Matthew AM, Double JA, et al. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer. 1995;71:1199–1203.
   PubMed Web of Science ®Google Scholar
• Kal HB, Karim ABMF, Hendriks HR. The efficacy of EO9 with radiation in experimental rat tumours. Ann Oncol. 1994;5(Suppl 5):88.
   Google Scholar
• Phillips RM, Hulbert PB, Bibby MC, et al. In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer. 1992;65:359–364.
   PubMed Web of Science ®Google Scholar
• Choudry GA, Stewart PA, Double JA, et al. A novel strategy for NQO1 (NAD(P)H: quinoneoxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer. 2001;85:1137–1146.
   PubMed Web of Science ®Google Scholar
• Siegel D, Beall H, Senekowitsch C, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 1992;31:7879–7885.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Naylor MA, Jaffar M, et al. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. J Med Chem. 1999;42:4071–4080.
   PubMed Web of Science ®Google Scholar
• Samuni AM, DeGraff W, Krishna MC, et al. Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity. Mol Cell Biochem. 2002;234-235:327–333.
   PubMed Web of Science ®Google Scholar
• Schellens JH, Planting AS, Van Acker BA, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994;86:906–912.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Gleason D, Young JM, et al. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008;180:116–120.
   PubMed Web of Science ®Google Scholar
• Puri R, Palit V, Loadman PM, et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol. 2006;176:1344–1348.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006;176:1349-53; discussion 53.
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Zorn KC, Shikanov S, et al. Marker lesion experiments in bladder cancer–what have we learned? J Urol. 2010;183:1678–1684.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, van der Heijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009;27:337–342.
   PubMed Web of Science ®Google Scholar
• Jain A, Phillips RM, Scally AJ, et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology. 2009;73:1083–1086.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol. 2012;187:1195–1199.
   PubMed Web of Science ®Google Scholar
• Yutkin V, Chin J. Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer. Expert Opin Investig Drugs. 2012;21:251–260.
   PubMed Web of Science ®Google Scholar
• Karsh L, Shore N, Saltzstein D, et al. Integrated results of two multicenter, randomised, placebo controlled, double blind, phase 3 trials (SPI-611/612) of single dose intravesical apaziquone immediately following resection in patients with nonmuscle invasive bladder cancer. J Urol. 2016;95(Supplement):e290.
   Google Scholar
• Witjes JA, Karsh L, Soloway M, et al. Improved efficacy of adjuvant, single dose intravesical apaziquone by timing post-resection in two double blind, randomised, placebo-controlled phase 3 studies in non-muscle invasive bladder cancer. J Urol. 2016;195(Supplement):e136.
   Google Scholar
• Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol. 2002;137:701–709.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Tonnesen F, Cassidy J, et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer. 1996;32A:2019–2022.
   PubMed Web of Science ®Google Scholar
• Connors TA. Bioreductive agents, hypoxic cells and therapy. Eur J Cancer. 1996;32A:1833–1834.
   PubMed Web of Science ®Google Scholar